Keytruda Small Cell Lung Cancer

Findings of the phase 1b keynote 028 trial were published in the journal of clinical oncology.

Keytruda small cell lung cancer.

The immunotherapy agent keytruda pembrolizumab had an overall response rate orr of 33 percent in a recent trial including patients with extensive stage small cell lung cancer sclc. Keytruda is already an established treatment option for non small cell lung cancer and this approval in small cell lung cancer demonstrates our commitment to bringing forward new treatment. User reviews for keytruda to treat small cell lung cancer. On june 17 2019 the food and drug administration granted accelerated approval to pembrolizumab keytruda merck for patients with metastatic small cell lung cancer sclc with disease.

Keytruda is a prescription medicine used to treat a kind of lung cancer called non small cell lung cancer nsclc. While these reviews might be helpful they are not a substitute for the expertise knowledge and judgement of healthcare practitioners. Keytruda pembrolizumab is used to treat advanced melanoma non small cell lung cancer small cell lung cancer head and neck squamous cell carcinoma classical hodgkin lymphoma primary mediastinal large b cell lymphoma urothelial carcinoma microsatellite instability high cancer gastric cancer esophageal cancer cervical cancer hepatocellular carcinoma merkel cell carcinoma renal cell.